RAMM Pharma Corp. Announces Corporate Update

Article content

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), is pleased to advise its shareholders that in accordance with its previously announced strategy of diversifying its product portfolio, in order to reduce its exposure to the strictly regulated environment of Cannabis-based products, it has launched the formulation and production of a full line of botanical-derived food supplements, through its subsidiary Hempoland Sp Zoo (“Hempoland”) under its Marishanti brand.

Article content

The Company expresses its recognition and thanks to the R&D, Quality and Production teams of Hempoland for their commitment and ongoing professional excellence.

Article content

Hempoland has successfully filed notification to the Competent Regulatory Authority for the first phase of its health supportive portfolio and has commenced sales in the EU with a view to international expansion including its online presence.

The product line available by April 30th, 2024, includes and will include:

The beneficial properties of the above have been extensively tested and documented in numerous academic reviews and research papers.

Additional SKUs, including non-restrictive functional mushroom, are under current development and Management expects to commence sales in 3Q2024.

Article content

Article content

The use of plant extracts is experiencing strong growth in the global market as consumers seek out natural and healthy products with beneficial properties. The urban population, with evolving lifestyles, has become increasingly health-conscious resulting in wider acceptance of alternative natural products fuelling the growth of botanical-derived food supplements. The global plant-extract market was estimated at USD 34.4 billion in 2022 and it is projected to grow at a CAGR of 12.3% to reach USD 61.5 billion by 2027 (source: www.marketsandmarkets.com).

About RAMM Pharma Corp.
RAMM Pharma is a leader in the field of cannabinoid pharmacology and product formulation for cannabis- based pharmaceuticals and other hemp-based products with a unique and diversified international production and sales platform. The Company operates an established pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant -derived cannabinoid pharmaceutical products that have been authorized for sale and/or compassionate use in several Latin American countries. RAMM also has a pipeline of new products, including registered hemp- based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at the company’s state-of-the-art, good-manufacturing-practice-certified formulation facility in Montevideo, Uruguay and Elblag, Poland.

Article content

In Europe, RAMM’s vertically integrated operations are based in Ragusa, Italy and Elbląg, Poland (60 kilometres east of Gdańsk), and include large extraction and processing facilities. RAMM Pharma includes wholly owned subsidiaries Canapar Corp., HemPoland S.p.a. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.

Additional information about the Company is available at www.wearerammpharma.com.

For further information, please contact:

José Roldan Interim CFO
+598 2513 99 58
info@rammpharma.com

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward
looking statements“) within the meaning of the applicable Canadian securities legislation. All statements, other than
statements of
historical
fact,
are
forward-looking
statements
and
are
based
on
expectations,
estimates
and
projections
as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations,
beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases
such as “expects”, or “does not expect”, “is
expected”, “anticipates” or “does not anticipate”, “plans”, “budget”,
“scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that
certain actions, events or results “may” or “could”, “would”, “might” or “wi ll” be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking statements. In this news release, forward looking statements
relate,
among
other
things,
the Company’s
strategies
and
objectives,
and
future expansion
plans.

Article content

These forward-looking statements are based on reasonable assumptions and estimates
of management of the
Company at the time such statements were made. Actual future results may differ materially as forward -looking
statements involve known and unknown risks, uncertainties and other factors which may cause the actual results,
performance
or
achievements
of
the
Company
to
materially
differ
from
any
future
results,
performance
or
achievements
expressed or implied by such forward-looking statements. Such factors, among other things, include: future growth
potential of the
Company; fluctuations in
general
macroeconomic conditions; fluctuations in
securities
markets;
expectations
regarding
the
size
of
the
Uruguayan,
Latin
American,
European
and
international
medical
and
recreational
cannabis markets and changing consumer habits; the ability of the Company to successfully achieve its business
objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insu rance to cover risks
and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production,
distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations.
Although the forward-looking statements contained in this news release are based upon what management of the
Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders
that actual results will be consistent with such forward -looking statements, as there may be other factors that cause
results
not
to
be
as
anticipated,
estimated
or
intended.
Readers
should
not
place
undue
reliance
on
the
forward
-looking
statements
and
information
contained
in
this
news
release.
The
Company
assumes
no
obligation
to
update
the
forward-
looking
statements
of
beliefs,
opinions,
projections,
or
other
factors,
should
they
change,
except
as
required
by
law.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information
contained
herein.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fab821be-3712-40a7-a7d8-da7ecb69b28b

Article content